N europsychiatric symptoms are common in dementia and are one of the reasons individuals with dementia are placed in nursing homes. 1, 2 There are no Food and Drug Administration (FDA)-approved medications for common dementia-associated behavioral symptoms such as wandering, agitation, and aggression. Nonetheless, antipsychotics are commonly used in nursing homes off-label to treat patients with dementia and behavioral symptoms, in addition to treating those with psychotic illnesses for whom antipsychotics are FDA approved (eg, schizophrenia). [3] [4] [5] [6] [7] [8] [9] In 2006, nearly 30% of nursing home residents in a large national study received an antipsychotic medication, of which 32% had no identified indication for use. 5 Recently, the Office of the Inspector General in the Department of Health and Human Services addressed this potential overuse, reporting that 22% of Medicare part D claims for atypical antipsychotics in nursing homes were not administered in compliance with Centers for Medicare and Medicaid Service standards for appropriate drug use. 10 Unfortunately, there are few nonpharmacologic means to treat behavioral symptoms of dementia, 11 and for decades physicians have used antipsychotics for symptom management. However, antipsychotics have limited evidence of overall efficacy for these symptoms, [12] [13] [14] and several studies suggest an increased mortality risk with their use in dementia. [14] [15] [16] [17] [18] After years of concern among clinicians and researchers about their potential overuse and propensity for adverse effects, [19] [20] [21] [22] [23] [24] the FDA issued a boxed warning in 2005 for the atypical antipsychotics, emphasizing their association with increased mortality when used for behavioral disorders in elderly residents with dementia. The warning was extended to conventional antipsychotics in 2008.
Although prior studies have documented the use of antipsychotics for outpatients with dementia in the Veterans Affairs (VA) Healthcare System, 1, 25 the rate of use of these agents among residents age 65 and older in VA nursing homes is unknown. The VA maintains 133 nursing homes, recently renamed Community Living Centers (CLCs), across the country to provide short-term and long-term care for eligible Veterans. The presence of an onsite pharmacy, along with centralized formulary, and utilization management through the Pharmacy Benefits Management (PBM) services, makes the VA CLC environment different from that of nursing homes outside the VA. Our aims for this study were to estimate the prevalence of antipsychotic use in older VA CLC residents and identify the patient and facility factors associated with antipsychotic use.
METHODS

Setting and Study Sample
The VA is the one of the largest integrated health care systems in the United States, with over 8 million Veterans enrolled and >5 million receiving care. 26, 27 In 2005, the average daily census of VA CLCs was about 12,000 Veterans. 28 We collected data on all residents aged 65 years or older admitted to any one of 133 VA CLCs between January 1, 2004 and June 30, 2005 . Residents were included if they were long-stay residents (defined as a minimum admission length of 90 d) and had at least 1 drug dispensing record during that time period. We excluded residents admitted for respite or hospice care. The Pittsburgh VA Research and Human Subjects Committees approved the study.
Study Design and Data Sources
All Veterans in a VA CLC are evaluated using the Minimum Data Set (MDS, current version 2.0), which is a clinical assessment for residents of nursing homes that serves as a standardized tool to evaluate their quality of care. 29 The data are collected from resident and staff interviews and reviews of resident records at baseline (ie, within 14 d of admission) and quarterly thereafter, or at the time of any significant change in health status. An electronic version of the MDS, which is stored in a central VA data warehouse, was made available through a data use agreement.
We linked each CLC resident's MDS data with all prescriptions dispensed during the first 90 days of their admission using VA PBM data. 30 For each dispensed drug, we collected start and stop date, medication name, medication strength, directions for use, and amount dispensed. To the MDS and drug use data we linked inpatient and outpatient International Classification of Diseases-9 (ICD-9) codes from the previous year from the VA Medical SAS datasets (Austin Information Technology Center in Austin, TX). We used this merged database to conduct all analyses. We also collected CLC facility characteristics (described below) from VA administrative sources because of the potential for nursing home organizational factors to affect antipsychotic prescribing. 4 
Study Outcome
Our primary outcome was the receipt of an antipsychotic at least once during the CLC stay. We use the terms "receipt," "use," and "prescribing" interchangeably because we assume that prescribed medications in the PBM database were received by the nursing home residents, who do not self-administer medications. For descriptive purposes, antipsychotics available in the VA at the time of this study were classified as atypical (ie, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone) or conventional (ie, chlorpromazine, fluphenazine, haloperidol, loxapine, molindone, perphenazine, trifluoperazine, thiothixene, thioridazine), and use was categorized as regularly scheduled or as needed (ie, "prn").
Patient and Facility Characteristics
Demographic variables included resident age, race/ ethnicity, sex, and education as obtained from the baseline MDS. We calculated a Charlson Comorbidity Score (range 0-34) for each resident using ICD-9 codes from the VA Medical SAS databases indicating the presence of 18 chronic conditions. 31, 32 We recorded the amount of assistance (ie, activities of daily living dependence) needed for 5 functional status items (bathing, dressing, grooming, toileting, eating), which is included in the baseline MDS for each resident. Each activity is rated from 0 (total independence) to 4 (complete dependence); the overall function score ranges from 0 to 20, where 20 denotes complete dependence in all activities of daily living. 33 We recorded additional relevant neurological/psychiatric health status variables, including aggressive behavior (based on the presence of verbally or physically abusive behavioral symptoms as documented on the MDS during the admission) and the use of physical restraints (yes/no, as described in the MDS). We used ICD-9 codes to define a diagnosis of posttraumatic stress disorder (309.81), other anxiety disorders (300.3, 300.01, 300.21, 300.00, 300.02, 300.09), and depression (296.2, 296.3, 298.0x, 300.4x, 309.1x, 311.xx, 301.12, 309.0x). [34] [35] [36] To create a polypharmacy variable (ie, the use of multiple medications), we identified the number of unique medications per resident, excluding psychiatric or dementia medications, from PBM data. We created separate dichotomous variables for the use of antidepressants, anxiolytic/hypnotics, and dementia treatment (ie, acetylcholinesterase inhibitors and memantine). Finally, we ascertained whether residents were residing in Alzheimer/dementia special care units based on information from section P of the MDS.
In addition to these demographic and health status variables, we also included facility variables describing location (ie, urban/rural) and census region (ie, northeast, midwest, south, west). Facility size was defined in terms of the number of beds [ie, small (< 60 beds), medium (60-120 beds), and large ( > 120 beds)] in each VA facility.
Indications for Antipsychotic Use
We classified each resident in the cohort into one of 3 mutually exclusive groups based on the potential indication (or lack of indication) for receipt of an antipsychotic. 3, [34] [35] [36] The first group included individuals who had a potentially appropriate indication for use of an antipsychotic [ie, either a psychiatric diagnosis in which psychotic symptoms are a prominent feature or a diagnosis of dementia and psychotic symptoms from the MDS (eg, hallucinations)]. 37 Psychiatric diagnoses were identified using the following inpatient or outpatient ICD-9 codes: 295.0-295.3, 295.5, 295.6-295.9 for schizophrenia and schizoaffective disorder; 295.4 for schizophreniform disorder; 296.4-296.8 for bipolar disorder; 298.8 for brief psychotic disorder; 293.0 and 293.1 for medical illnesses or delirium with manic or psychotic symptoms; 298.9 for psychosis not otherwise specified or atypical psychosis; 297.x for delusional disorder; 292.81 for drug-induced delirium; and 296.14 for manic affective disorder with psychotic behavior. 34, 35 Individuals with Tourette (ICD-9 307.23) or Huntington disease (ICD-9 333.4) also were included in this group. A small proportion (7%) of residents with psychotic symptoms reported in MDS did not have dementia (ICD-9 codes 331.0, 290.4, 331.82, 331.19, 046.1, 331.11, 290.0, 331.2, 797, 294.1, and 290.2) but were also assigned to the group with a potentially appropriate indication.
We then categorized the remaining residents without documentation of psychiatric diagnoses or psychosis (as defined above) into 2 groups defined by whether or not they had dementia. Both of these groups were considered to be potentially inappropriate recipients of antipsychotics based on accepted indications for these drugs. 10 
Analysis
We summarized all variables using descriptive statistics. We described the proportion of CLC residents receiving an antipsychotic and reported the indication for use of an antipsychotic among antipsychotic users. Characteristics of antipsychotic users and nonusers were compared with w 2 or t tests, as appropriate. We examined the relationship between antipsychotic use and each of our variables using logistic regression models to identify those factors independently associated with antipsychotic use. Preliminary variable selection was based on logistic regression with backward elimination using an a of 0.10; we recognize that this approach to model selection without adjusting for cor-relation could be anticonservative (ie, including extra variables for consideration in the final model), particularly for facility-level predictors. For those variables that remained statistically significant, we subsequently used generalized estimating equations to account for clustering of residents within facility and to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for antipsychotic use. 38 The adjustment for clustering made very little difference in the final quantitative or qualitative results. All analyses were carried out using SAS version 9.0 (Cary, NC).
RESULTS
The final cohort included 3692 Veterans over age 65 residing in 133 VA CLCs. Residents were predominately white (80.7%), and very few were female (2.8%) ( Table 1) . Over half of Veterans in CLCs (52.5%) used Z9 medications, and half (50.0%) received an antidepressant. About 10% of the cohort resided in an Alzheimer/dementia special care unit. Slightly over a third (36.8%) of residents had a psychosis diagnosis or psychotic behavior and thus a potentially appropriate indication for an antipsychotic.
Overall, 948/3692 (25.7%) Veterans used an antipsychotic during their CLC stay. The vast majority (90.6% of users) received "atypical" antipsychotics, with 6.6% of antipsychotic use being limited to "prn" only (data not shown). Antipsychotic users were more likely than nonusers to have aggressive behavior (19.0% vs. 5.1% P < 0.001) and were more likely to receive antidepressants, anxiolytic/hypnotics, and medications for dementia (P < 0.001 for each) ( Table 1) . Among Veterans who received an antipsychotic, 59.3% had psychosis or psychotic behavior and a documented indication for use, whereas the remaining 40.7% had no evidence of psychosis (including 14.7% with dementia but no documented psychosis and 26.1% without dementia or documented psychosis).
Characteristics Associated With Antipsychotic Use
In unadjusted analyses, older residents (older than 85 y) and those with higher Charlson Comorbidity Scores were less likely to receive antipsychotics ( Table 2) . Residents without dementia or psychosis were less likely than those with psychosis to receive an antipsychotic (OR 0.20, 95% CI, 0.17-0.24); however, those with dementia but no psychosis were as likely to receive an antipsychotic as were those with psychosis (OR 0.98, 95% CI, 0.77-1.24). Those residing in Alzheimer/dementia special care units and in larger facilities had higher unadjusted odds of antipsychotic use ( Table 2 ).
In the multivariable analysis, the only demographic factor associated with antipsychotic use was age, with older Veterans significantly less likely to receive antipsychotics (OR 0.77, 95% CI, 0.64-0.93 for age 75-84, OR 0.67, 95% CI, 0.51-0.88 for those older than 85 y) ( Table 2 ). The estimated OR of receiving an antipsychotic decreased with increasing comorbidity (OR 0.89 per unit increase in the Charlson Score, 95% CI, 0.86-0.93). Residents with aggressive behavior (OR 2.74, 95% CI, 2.04-3.67) and polypharmacy (9+ drugs; OR 1.84, 95% CI, 1.41-2.40) were more likely to receive antipsychotics, as were users of antidepressants (OR 1.37, 95% CI, 1.14-1.66), anxiolytic/hypnotics (OR 2.30, 95% CI, 1.64-3.23), or drugs for dementia (OR 1.52, 95% CI, 1.21-1.92). Veterans residing in an Alzheimer/dementia special care unit were significantly more likely to use an antipsychotic (OR 1.66, 95% CI, 1.26-2.21). Veterans with dementia but no psychosis were about as likely as those with an evidence-based indication to receive an antipsychotic (OR 1.10, 95% CI, 0.82-1.47).
DISCUSSION
In a national sample of older Veterans residing in VA nursing homes (CLCs), more than 1 in 4 were prescribed an antipsychotic. In addition, 4 out of every 10 antipsychotic users in VA CLCs did not have a clear evidence-based indication for use (ie, psychosis or psychotic behavior). Residents with aggressive behavior, those who were younger and using more medications, and those residing in Alzheimer/ dementia special care units were more likely to receive antipsychotics.
Rates of antipsychotic use in VA CLCs are similar to rates in non-VA nursing homes, which range from 25% to 32%. [3] [4] [5] [6] [7] [8] [9] The proportion of antipsychotic users in VA CLCs without an evidence-based indication for use is also similar to the proportion outside the VA. 8 Our rates of antipsychotic use are lower than 49% reported in a previous analysis of VA CLCs that included residents of all ages who were institutionalized for at least a year 39 ; it is likely that younger Veterans confined to nursing homes have a higher prevalence of psychiatric disease, which was not measured in the prior study and likely explains the higher rates.
Residents with dementia but no evidence of psychosis were about as likely to receive antipsychotics in VA CLCs as those with documented psychosis. These individuals may have behavioral symptoms that are troublesome but do not necessarily fit the established criteria for use of antipsychotics, either as per the structured package label or through Centers for Medicare and Medicaid Services surveyor guidance on potentially inappropriate medication use. 40 We did include an indicator for aggressive behavior from the MDS and found that residents with aggressive behavior had almost 3 times greater odds of antipsychotic use. It is unclear whether clinicians are using antipsychotics in residents with dementia without considering the risks, or whether they are considering the risks but have determined that the behavioral symptoms are sufficiently problematic (either for the resident or their family) that the potential benefits outweigh the risks of therapy. Our findings of lower antipsychotic use in older nursing home residents could support the notion that clinicians are basing prescribing decisions on a risk/benefit analysis, if we presume that clinicians view older, and hence more frail, patients with dementia as higher risk because they are more likely to suffer adverse events (falls, worsening confusion). Ultimately, we are unable to answer these questions without examining individual medical records, and even then, unfortunately, the documentation may not exist.
Veterans residing in Alzheimer/dementia special care units had 66% greater odds of receiving an antipsychotic, even after adjusting for age, clinical indication, comorbidity, and aggressive behavior. It is possible that residents in these dementia care units have more severe dementia or behavioral or neurocognitive symptoms that cannot be captured in currently available databases. However, one might expect that these units, whose staff likely have expertise in treating Alzheimer and other types of dementia, 41 would be more likely to use nonpharmacologic treatments. It may be that they are, in fact, using more nonpharmacologic treatments while also using more medication. Further work is needed to better understand why residents in dementia special care units have a higher probability of use of antipsychotics and whether this association also holds outside the VA.
We also found that polypharmacy and the use of other psychoactive medications, including anxiolytic/hypnotics, antidepressants, and medications for dementia, were associated with greater use of antipsychotics. This association remains after statistical adjustment, making it unlikely that polypharmacy is simply a surrogate for more severe behavioral problems. Polypharmacy may reflect greater health services use within the VA Healthcare System before admission, which could potentially lead to greater access to antipsychotics. Once again, without access to detailed medical records it would be difficult to know for sure the reasons for this association. Nonetheless, polypharmacy is one of the most important risk factors for functional status decline, increased health services utilization, adverse drug events, and death among older adults, and it is addressible. 42, 43 The association between polypharmacy and the use of antipsychotics in nursing homes is an additional reason for clinicians to evaluate the need for each medication in these patients and to discontinue those that appear to be unnecessary. What should clinicians do for the troublesome neurocognitive symptoms seen in nursing home residents with dementia, who may be receiving antipsychotics currently? Unfortunately, successful interventions that address inappropriate prescribing in nursing homes can be resource intensive. [44] [45] [46] The VA is undertaking several initiatives to address the use of antipsychotics in VA nursing homes, including increasing the availability and integration of psychologist services, and piloting behavioral management programs such as the Staff Training in Assisted Living Residences in VA and the Activators Behaviors and Consequences models. 47, 48 The VA is also supporting efforts for better documentation in the medical record of risk/benefit discussions regarding the use of these antipsychotic agents.
Although our study is the first to address this important topic in VA nursing homes, there are limitations to consider. First, our data were collected before the 2005 FDA boxed warning and thus may not reflect current practice. However, ours are the most recent data available to address the topic of medication use in VA CLCs, and despite the lack of an FDA warning in 2004-2005, publications and reports already had appeared in print about the risks of these agents. 1 Second, our study is cross-sectional, and as such we cannot make any causal inferences. In addition, although we required at least a 90-day stay for persons in the cohort, we did not include a measure of the length of each nursing home stay; we cannot know whether length of stay played a role in antipsychotic receipt. Third, we were not able to capture additional organizational factors that may be important, such as nurse or nurse assistant staffing ratios, staff turnover, and presence of geriatricians, geriatric specialty trained pharmacists and nurses, or geriatric psychiatrists. However, we did evaluate a number of facility characteristics, none of which was independently associated with antipsychotic use. Fourth, some antipsychotics can be used off-label for indications other than neurocognitive symptoms of dementia (eg, adjunct treatment of depression 49 ), and we are not able to capture those indications in our analysis, although we did control statistically for the use of antidepressants. Finally, our study may not be generalizable to younger Veterans in nursing homes or to women, who are not well represented in our sample.
In summary, antipsychotic prescribing is common in older VA nursing home residents, including residents without a documented evidence-based indication for use. Rates of use are similar to rates in non-VA nursing homes. Quality improvement efforts are needed to reduce potentially inappropriate antipsychotic prescribing and increase the use of nonpharmacological behavior modification approaches. These efforts are underway in the VA, and their effectiveness should be carefully evaluated.
